IMR Press / EJGO / Volume 25 / Issue 5 / pii/2004234

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.


Inhibitors of angiogenesis in therapy of ovarian cancers

Show Less
1 Division of Gynecological Oncology. Department of Oncology, University of Medical Sciences, Poznan (Poland)
2 Department of Molecular Biology Centre of Oncology Maria Sklodowska-Curie Memorial Institute, Gliwice (Poland)
Eur. J. Gynaecol. Oncol. 2004, 25(5), 562–567;
Published: 10 October 2004

The capacity to induce growth of blood vessels represents one of the phenotypic traits of neoplastic cells. Several preclin­ical studies prove that the inhibition of growth of peri-neoplastic blood vesssels leads to restricted growth of primary tumours and of metastases. Nevertheless, clinical studies indicate that angiogenesis inhibitors are not such effective drugs as might be expected on the basis of studies conducted on animals. In this article we would like to draw the readers' attention to diver­gencies between preclinical and clinical results, in particular to those related to ovarian cancers. In the treatment of ovarian cancers, angiogenesis inhibitors combined with other drugs may prove to represent a relatively effective therapeutic approach.

Angiogenesis inhibitors
Ovarian cancer
Back to top